کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
10746096 | 1048752 | 2012 | 5 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
A guide to dosing in the treatment of cervical dystonia and blepharospasm with Xeomin®: A new botulinum neurotoxin A
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
کلمات کلیدی
موضوعات مرتبط
علوم زیستی و بیوفناوری
بیوشیمی، ژنتیک و زیست شناسی مولکولی
سالمندی
پیش نمایش صفحه اول مقاله

چکیده انگلیسی
The recommended dose for patients with CD is 120 U/treatment, with administration intervals normally between 3 and 6 months. However, clinical studies have found Xeomin to be safe and effective at doses up to 400 U in both previously treated and treatment-naïve patients. The recommended starting dose in patients with blepharospasm is 2.5-5.0 U/injection site. Patients can be switched using a 1:1 conversion ratio from Botox® (onabotulinumtoxinA, Allergen Inc., Irvine, CA, USA) to Xeomin without any loss of efficacy or safety concerns. Xeomin does not differ from Botox in terms of its potency, onset, diffusion profile, or duration and waning of effect. It is the only botulinum treatment that is stable for up to 3 years at room temperature. Xeomin offers a new and important treatment option for movement disorders.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Parkinsonism & Related Disorders - Volume 18, Issue 5, June 2012, Pages 441-445
Journal: Parkinsonism & Related Disorders - Volume 18, Issue 5, June 2012, Pages 441-445
نویسندگان
Fernando L. Pagan, Andrew Harrison,